Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/18/2003WO2003045392A3 Use of n-(indolcarbonyl-)piperazine derivatives
09/18/2003WO2003045360A3 Use of gaba for the treatment of intestinal inflammations
09/18/2003WO2003041681A3 Lipid carrier compositions with enhanced blood stability
09/18/2003WO2003037897A3 Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
09/18/2003WO2003037308A3 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion
09/18/2003WO2003035861A3 Thrombin-cleavable chimeric proteins
09/18/2003WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
09/18/2003WO2003033808A3 Composition and method for treating diabetes
09/18/2003WO2003033692A3 Use of the adenoviral e2 late promoter
09/18/2003WO2003032928A3 Therapeutic composition and use
09/18/2003WO2003028600B1 Wipe formulation
09/18/2003WO2003026584A3 Stem cells of the islets of langerhans and their use in treating diabetes mellitus
09/18/2003WO2003024489A3 Combination of a nsaid and a pde-4 inhibitor
09/18/2003WO2003024472A3 Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
09/18/2003WO2003024442A3 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
09/18/2003WO2003016781A3 Surface plasmon enhanced illumination system
09/18/2003WO2003011851A3 Aromatic hydroxamic acid derivatives useful as hdac inhibitors
09/18/2003WO2003011274A3 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
09/18/2003WO2003007926A3 Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions
09/18/2003WO2003005980A3 Cosmetic and dermatological preparations containing carnitine
09/18/2003WO2002103015A3 Abca10 transporter
09/18/2003WO2002102388A3 Active ingredient combination of e.g. galanthamine or deoxypeganine and e.g. acamprosate or memantine for treating an addiction such as alcoholism
09/18/2003WO2002102317A3 Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid
09/18/2003WO2002100323A3 METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS
09/18/2003WO2002095704A8 Use of nf-kappa-b inhibitors to treat dry eye disorders
09/18/2003WO2002085410A3 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
09/18/2003WO2002083700B1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
09/18/2003WO2002083184A3 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
09/18/2003WO2002078627A3 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
09/18/2003WO2002077267A3 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
09/18/2003WO2002076925A3 Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
09/18/2003WO2002072790A3 Tsg101-gag interaction and use thereof
09/18/2003WO2002066646A3 Neurotransmission-associated proteins
09/18/2003WO2002062750A9 Cannabinoid receptor ligands
09/18/2003WO2002062391A3 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
09/18/2003WO2002053177A3 Agents and methods for treating pain
09/18/2003WO2002038557A9 Benzoylbenzofurane derivatives for treatment of cardiac arrhythmia
09/18/2003WO2002036110A9 Oral self-emulsifying formulations of pyranone protease inhibitors
09/18/2003WO2002031181A3 Flea synaptic vesicle nucleic acid molecules, proteins and uses thereof
09/18/2003WO2002011706A3 Drugs for sex dysfunctions
09/18/2003US20030177511 Antitumor, anticancer agents
09/18/2003US20030176853 Sustained release delivery systems for solutes
09/18/2003US20030176848 Incorporating antimicrobial agent comprising an oxazolidinone compound into medical device
09/18/2003US20030176822 Method of treating restless leg syndrome
09/18/2003US20030176784 Labeling targeting agents with gallium-68 and gallium-67
09/18/2003US20030176726 Selective retinoid agonists
09/18/2003US20030176706 Process for the preparation of [S(-) amlodipine - L (+)- hemitartarate]
09/18/2003US20030176702 N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
09/18/2003US20030176701 Di-or triaza-spiro [4,5] decane derivatives
09/18/2003US20030176699 Purine inhibitors of protein kinases, G proteins and polymerases
09/18/2003US20030176695 Such as N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide for treatment of disorders of the central nervous system; neuroprotectants
09/18/2003US20030176678 Viricides, antitumor agents, antiproliferative agents, anticancer agents; genetic engineered Dna
09/18/2003US20030176670 Multivalent macrolide antibiotics
09/18/2003US20030176668 C-nitroso compounds and use thereof
09/18/2003US20030176667 Transfroming growth factor; drug design
09/18/2003US20030176666 Hypothalamus-specific polypeptides
09/18/2003US20030176661 Novel antibody with specificity for colon cancer
09/18/2003US20030176620 Synthetic methods for polyphenols
09/18/2003US20030176514 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate
09/18/2003US20030176511 Compositions and methods for treating cardiovascular disorders
09/18/2003US20030176510 Acetamidobenzamide compounds for neurodegenerative disorders
09/18/2003US20030176509 Methods and products related to 16-HETE analogs
09/18/2003US20030176506 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells
09/18/2003US20030176505 Analgesic compositions comprising anti-epileptic compounds and methods of using same
09/18/2003US20030176504 Administering a therapeutically effective amount of an alpha2delta ligand other than gabapentin or tiagabine, or pharmaceutically acceptable salt thereof
09/18/2003US20030176503 Treating hepatitis C viral infections with thiosemicarbazone compounds
09/18/2003US20030176502 Pravastatin pharmaceutical formulations and methods of their use
09/18/2003US20030176501 For use in inhibiting HMG-CoA reductase; therapy and prophylaxis of hypercholesterolemia, atherosclerotic disease
09/18/2003US20030176500 Medium chain fatty acids applicable as antimicrobial agents
09/18/2003US20030176499 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
09/18/2003US20030176498 Inhibitors of alpha4mediated cell adhesion
09/18/2003US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments
09/18/2003US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof
09/18/2003US20030176495 HIV Integrase inhibitors
09/18/2003US20030176494 Novel coumarin and chromene compounds and methods of preparation and use thereof for treating or preventing viral infections
09/18/2003US20030176493 Having antineoplastic activity; antioxidant activity; and inhibit DNA topoisomerase II enzyme
09/18/2003US20030176492 Having antimalarial activity against the proliferation of malarial parasites and is therefore useful as an antimalarial drug
09/18/2003US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer
09/18/2003US20030176489 Glyt-1 inhibitors
09/18/2003US20030176488 Method for treating depression
09/18/2003US20030176487 For therapy and prophylaxis of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders
09/18/2003US20030176486 For use as an inhibitor of lipopolysaccharides (LPS)
09/18/2003US20030176485 Calcium receptor active compounds
09/18/2003US20030176484 Administering to the mammal an effective amount of a GSK-3 beta (glycogen synthase kinase-3 beta) to promote bone formation and treat bone metabolic diseases such as osteoporosis
09/18/2003US20030176482 Imidazole derivatives or their salts
09/18/2003US20030176481 Novel imidazole derivatives with anti-inflammatory activity
09/18/2003US20030176480 Amide-type triazole compounds
09/18/2003US20030176479 Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/18/2003US20030176478 For selectively modulating the activation, repression, agonism and antagonism effects of the glucocorticoid receptor in a patient; for therapy and prophylaxis of obesity, diabetes, depression, neurodegeneration or an inflammatory disease
09/18/2003US20030176476 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
09/18/2003US20030176475 For therapy of disorders of the gastrointestinal system, and of the central nervous system
09/18/2003US20030176474 Modulators of Rho C activity
09/18/2003US20030176473 For use in cancer therapy
09/18/2003US20030176472 Method of tizanidine therapy
09/18/2003US20030176470 For prophylaxis and/or therapy of skin diseases and/ or inflammation responses of the skin
09/18/2003US20030176467 Nicotine compositions
09/18/2003US20030176466 For controlling parasites in or on an animal
09/18/2003US20030176465 Cyclic amino acid derivatives
09/18/2003US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally
09/18/2003US20030176462 Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of all mood disorders, adaptation disorders or mixed anxiety-depression disorders
1 ... 5337 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 5348 5349 5350 5351 5352 5353 5354 5355 5356 5357 ... 7860